Uncovering novel targets for cancer chemoprevention

Area of Science:

• Oncology
• Molecular Pharmacology
• Cancer Chemoprevention

Background:

• Aberrant expression of G1 cyclins (D-type and E-type) is observed in bronchial preneoplasia and lung cancers.
• Tobacco carcinogens and chemopreventive agents like all-trans-retinoic acid (RA) affect these cyclins in human bronchial epithelial cells.
• D-type cyclins are implicated as key molecular targets for cancer chemoprevention.

Purpose of the Study:

• To explore retinoid regulation mechanisms of D-type cyclins in lung cancer chemoprevention.
• To investigate the role of phosphorylation and specific kinases in retinoid-mediated cyclin regulation.
• To validate D-type cyclins as targets for clinical cancer chemoprevention.

Main Methods:

• Treatment of human bronchial epithelial (HBE) cells with tobacco carcinogens and all-trans-retinoic acid (RA).
• Analysis of cyclin D1 and D3 expression and degradation pathways, including proteasomal degradation and phosphorylation.
• Use of phospho-specific antibodies, glycogen synthase kinase (GSK) inhibitors, small interfering RNAs (siRNAs), and gene profiling (UBE1L).
• Translation of preclinical findings into proof-of-principle clinical trials.

Main Results:

• Retinoid chemoprevention is mechanistically linked to the proteasomal degradation of cyclin D1 and cyclin D3.
• Phosphorylation at Threonine 286 stabilizes cyclin D1, a process influenced by retinoids.
• Glycogen synthase kinase (GSK) plays a role in retinoid regulation of cyclin D1, but not cyclin D3.
• UBE1L was identified as a key factor in retinoid regulation of cyclin D1.
• Clinical trials confirmed that chemopreventive agents can target D-type cyclins.

Conclusions:

• D-type cyclins are validated molecular targets for lung cancer chemoprevention.
• Retinoid-induced proteasomal degradation of cyclin D1 and D3 is a key mechanism in chemoprevention.
• Targeted combination regimens affecting D-type cyclins show promise for cancer prevention.